Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

NCT05437510 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

8057

Enrollment

INDUSTRY

Sponsor class

Conditions

RSV Immunization
Healthy Volunteer

Interventions

BIOLOGICAL: Nirsevimab

Sponsor

Sanofi Pasteur, a Sanofi Company

Collaborators

[object Object]